AMRN Market Analysis
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 500.00
EPS (TTM)$-1.20-94.2% YoY
Profit margin-14.6%HEALTHCARE
Market cap$299.0MMicro cap
Valuation
- Forward P/E
- 500.00
- PEG ratio
- 0.81
- P/B
- 0.68
- P/S (TTM)
- 1.61
- EV/EBITDA
- -5.80
Profitability & growth
- ROE (TTM)
- -6.0%
- Operating margin
- -28.4%
- Revenue growth YoY
- -42.0%
- Dividend yield
- —
- Beta
- 0.80
Last earnings
Jul 29, 2026 · Estimate $-0.21 · Reported $-0.07
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Amarin Corporation PLC
Company profileAmarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- ONE CENTRAL PLAZA, DUBLIN, IRELAND
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$299.0M
Shares outstanding$21.0M
52W high$20.90
52W low$12.96
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent